Evolus Stock Price, News & Analysis

Evolus, Inc. (Nasdaq: EOLS) has promoted Crystal Muilenburg to Chief Marketing Officer, effective immediately, enhancing its marketing leadership. Muilenburg brings over 20 years of experience, particularly in aesthetics from her time at Allergan. David Moatazedi, CEO, emphasized the company’s growth trajectory post-ITC legal case, focusing on expanding Jeuveau^® sales and international presence. Concurrently, Michael Mazen Jafar will leave his position as Chief Commercial Officer to pursue another opportunity. Evolus is poised for significant market expansion.

Evolus, Inc. (NASDAQ: EOLS) reported preliminary net revenues of $20.6 million for Q4 2020, marking a 16% increase over Q3 2020. For the entire year, the company achieved $56.5 million in total revenue, driven primarily by Jeuveau^® sales. The company also noted an expansion to over 5,600 ordering accounts and a record re-order rate of 71.6% in Q4. Legal matters, including a case with Abbvie and Medytox, were resolved, and while pricing increased during the ITC review period, actual revenue was nominal during that timeframe.

Evolus, a performance beauty company, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. The event will feature a fireside chat and one-on-one meetings from 1:00 PM to 1:30 PM ET. An audio webcast of the chat will be available on Evolus' investor relations website, with replays accessible for 90 days. Evolus is known for its innovative products, including Jeuveau®, a neurotoxin dedicated to aesthetics, approved by the FDA in 2019.

AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS), and Medytox have settled all litigation related to Jeuveau®, resolving a case filed by Medytox against Evolus. Under the agreement, AbbVie and Medytox release claims against Evolus and allow the commercialization of Jeuveau® in the U.S. and Nuceiva™ elsewhere. Evolus will pay milestone and royalty fees and issue stock to Medytox. This settlement follows an ITC decision from December 16, 2020, that found misappropriation of Medytox's trade secrets but does not affect ongoing legal matters with Daewoong.

Evolus, Inc. (NASDAQ: EOLS) announced the U.S. International Trade Commission (ITC) partially affirmed a Section 337 violation against the company regarding the Jeuveau^® product. The ITC has imposed a 21-month ban on the import, sale, and marketing of Jeuveau^® in the U.S., a reduction from the ALJ's proposed 10-year ban. Evolus plans to post a bond to continue sales during the 60-day presidential review period. CEO David Moatazedi expressed commitment to overturning the ITC decision and thanked stakeholders for their support.

Evolus, Inc. (Nasdaq: EOLS) announced the promotion of Michael Mazen Jafar to Chief Commercial Officer and Jeff Plumer to General Counsel, effective November 1, 2020. Jafar, previously Chief Marketing Officer since June 2018, successfully launched Jeuveau®, a leading aesthetic neurotoxin. Plumer has been instrumental in key milestones, including the company's IPO. CEO David Moatazedi acknowledged their contributions and emphasized their roles in preparing Evolus for future growth.

Evolus, Inc. reported Q3 2020 net revenue of $17.7 million, marking a 34% increase compared to Q3 2019. The results included $16.9 million from U.S. Jeuveau® sales. Gross margin was 72.5%, and GAAP operating expenses decreased by 38% to $21.6 million. The GAAP net loss reduced by 57% to $11.5 million. Cash reserves grew to $110.1 million from $84.8 million in Q2 2020, bolstered by a $40 million investment from Daewoong Pharmaceutical. Key highlights include increased demand for Jeuveau® and a growth in purchasing accounts.

Evolus reported Q2 2020 net revenue of $7.8 million, a significant increase from $2.3 million in Q2 2019, largely driven by a recovery in business as COVID-19 restrictions eased. Approximately 90% of revenue was generated in the latter half of the quarter. The company's gross margin improved to 75%, and operating expenses saw a reduction of 34% to $24.7 million. A $40 million convertible note financing and a pro forma cash position of $124.8 million bolster financial stability. Key marketing initiatives for the Jeuveau® product have shown promise.

Evolus, Inc. (NASDAQ: EOLS) announced it will report its second quarter 2020 financial results on August 10, 2020, after U.S. markets close. The company, known for its customer-centric approach and breakthrough products, will hold a conference call at 4:30 p.m. ET the same day to discuss the results. Dial-in details for the call are provided, along with a replay option available until August 17, 2020. Evolus is recognized for its FDA-approved neurotoxin Jeuveau^®, specifically targeting aesthetics.